help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 8, 2008
Endocrinology, doi:10.1210/en.2008-0117
A more recent version of this article appeared on August 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
149/8/3799    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albanito, L.
Right arrow Articles by Maggiolini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albanito, L.
Right arrow Articles by Maggiolini, M.

Submitted on January 25, 2008
Accepted on April 29, 2008

EGF INDUCES GPR30 EXPRESSION IN ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER CELLS

Lidia Albanito, Diego Sisci, Saveria Aquila, Elvira Brunelli, Adele Vivacqua, Antonio Madeo, Rosamaria Lappano, Deo Prakash Pandey, Didier Picard, Loredana Mauro, Sebastiano Andò, and Marcello Maggiolini*

Department of Pharmaco-Biology, Department of Ecology, Department of Cell Biology, University of Calabria, 87030 Rende, Italy; Department of Cell Biology, University of Genève, 30, quai Ernest-Ansermet,1211 Genève 4, Switzerland

* To whom correspondence should be addressed. E-mail: marcellomaggiolini{at}yahoo.it.

Different cellular receptors mediate the biological effects induced by estrogens. In addition to the classical nuclear estrogen receptors (ER) {alpha} and {beta}, estrogen also signals through the seven-transmembrane G-protein-coupled receptor (GPCR) GPR30. Using as a model system SkBr3 and BT20 breast cancer cells lacking the classical estrogen receptor (ER), the regulation of GPR30 expression by 17{beta}-estradiol, the selective GPR30 ligand G-1, Insulin Growth Factor-1 (IGF-1) and Epidermal Growth Factor (EGF) was evaluated. Transient transfections with an expression plasmid encoding a short 5'-flanking sequence of the GPR30 gene revealed that an AP-1 site located within this region is required for the activating potential exhibited only by EGF. Accordingly, EGF up-regulated GPR30 protein levels which accumulated predominantly in the intracellular compartment. The stimulatory role elicited by EGF on GPR30 expression was triggered through rapid ERK phosphorylation and c-fos induction which was strongly recruited to the AP-1 site found in the short 5'-flanking sequence of the GPR30 gene. Of note, EGF activating the EGFR-MAPK transduction pathway stimulated a regulatory loop which subsequently engaged estrogen through GPR30 to boost the proliferation of SkBr3 and BT20 breast tumor cells. The up-regulation of GPR30 by ligand-activated EGFR-MAPK signaling provides new insight into the well-known estrogen and EGF cross-talk which, as largely reported, contributes to breast cancer progression. On the basis of our results the action of EGF may include the up-regulation of GPR30 in facilitating a stimulatory role of estrogen even in ER-negative breast tumor cells.


Key words: estrogen • estrogen receptor • GPR30 • breast cancer cells • EGF







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society